Cargando…
Safety review of hydroxyprogesterone caproate in women with a history of spontaneous preterm birth
17-alpha-hydroxyprogesterone caproate (17P) has been in use for prevention of recurrent preterm birth since 2003 when the Meis trial was published. A requirement for Food and Drug Administration approval of 17P was a confirmatory trial, called “PROLONG”, which was recently completed, but did not rep...
| Autores principales: | , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Nature Publishing Group US
2020
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8049867/ https://www.ncbi.nlm.nih.gov/pubmed/33057132 http://dx.doi.org/10.1038/s41372-020-00849-y |